Biomarkers – Multimedia

The SomaScan Assay is an ideal high throughput platform for identifying proteins that may be involved in disease pathology, as it offers a highly sensitive method of quantifying proteins in different biologic fluids such as serum, plasma, urine and cerebrospinal fluid.

Developed for performance in human serum and plasma, the SomaScan Assay v4.1 can measure approximately 7,000 unique human protein analytes in small volumes of biological samples.

The Ella instrument by Bio-Techne automates every step of the immunoassay workflow, helping to minimize user error while ensuring highly precise and reproducible results.

Speaking at ‘Advances in Proteomics & Metabolomics’ 2022, Erik Johnson from Emory University, presented their talk on proteomics in Alzheimer’s disease.

Spatial biology relies on validated reagents to map proteins in tissue. While immunofluorescence is widely used, there are no universal guidelines for antibody validation, posing challenges for accuracy and reproducibility in research.

Rather than choosing between the detail of single-cell RNA sequencing and the in situ capabilities of conventional immunohistochemistry, spatial phenotyping allow you to visualize and quantify dozens of biomarkers in a single tissue sample while maintaining cellular and sub-cellular detail.

Only a small amount of cell-free DNA (cfDNA) can be found in circulation, therefore efficient and highly sensitive technologies such as next-generation sequencing (NGS) are typically being used to detect this biomarker.

Speaking at The Landscape of Cancer Research 2022 online symposium, Sofia Lourenco of Cancer Research Horizons delivered her talk on the challenges facing the future of cancer immunotherapies.

Highly multiplexed spatial biomarker analysis has demonstrated the potential to advance our current understanding of the immune system and its role in cancer.

Rare cells play pivotal roles in disease initiation, maintenance and progression. Yet, identifying these cells remains a difficult task for low-plex technologies, as it is not always clear a priori which biomarkers distinguish rare phenotypes from the remaining population.